HIPAA Alert: Potential Data Breach Learn More

Search
Close this search box.

Moorestown RCCA Physicians Named to South Jersey List of 2022’s Top Doctors for Women

Offering patients the latest in cutting-edge treatments, including immunotherapies and targeted therapy, as well as access to a wide range of clinical trials, the Moorestown office of Regional Cancer Care Associates (RCCA) salutes the five members of its staff recently named to South Jersey Magazine’s list of Top Physicians for Women in 2022 – Hematology/Oncology. Honorees, chosen by their peers and readers of the publication, include RCCA’s Dr. Seth Berk, Dr. Maurice Cairoli, Dr. James Lee, Dr. Stephen Wallace and Dr. Rachel Levenbach.

These physicians are among RCCA’s more than 90 cancer specialists who treat patients at more than 25 RCCA care centers in New Jersey, Connecticut, Maryland and the Washington, DC, area. Those oncologists see more than 23,000 new patients each year and provide care to more than 225,000 established patients, collaborating closely with their patients’ other physicians. They offer patients the latest in cutting-edge treatments, including immunotherapies and targeted therapy, as well as access to a wide range of clinical trials. In addition to serving patients who have solid tumors, blood-based cancers and benign blood disorders such as anemia, RCCA care centers also provide infusion services to people with a number of non-oncologic conditions, including multiple sclerosisCrohn’s diseaseasthma and rheumatoid arthritis.

To learn more about RCCA, call 844-928-0089 or visit RCCA.com.

we are here for you

For more information or to schedule an appointment,
call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.

RELATED ARTICLES

Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.